ArticleTranslational lung cancer research2025
Assessing the prognosis of metastatic or recurrent non-small cell lung cancer in the era of modern systemic therapies: a multivariable analysis of 343 patients treated in Poland.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Beyond the Scan: Adapting Multimodal Lung Cancer Screening for Central and Eastern Europe-Overcoming Systemic Barriers and Epidemiological Confounders.Medical sciences (Basel, Switzerland) · 2026Review
- Development and validation of a multi-center prognostic model for predicting survival in non-small cell lung cancer using pulmonary and hematological data.Journal of thoracic disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prognostic factor assessment in metastatic or recurrent non-small cell lung cancer (NSCLC) is based primarily on older studies from the chemotherapy era or modern trials evaluating the safety and efficacy of specific treatment regimens. However, studies that compare prognostic factors across immunotherapy, molecularly guided therapy, and chemotherapy within the same real-world context remain scarce. This gap is addressed by the present study which aims to retrospectively evaluate prognostic factors for overall survival in patients treated with diverse systemic therapies. Methods: The analysis included 343 patients with metastatic or recurrent NSCLC treated between 2006 and 2022. Treatment consisted of immune checkpoint inhibitors (ICI) in 176 patients, epidermal growth factor receptor (EGFR) inhibitors in 72, ALK/ROS inhibitors in 25 and chemotherapy in 70. Adenocarcinoma was diagnosed in 210 patients, squamous-cell cancer in 110 and other types of NSCLC in 23. Several host and tumor-related variables evaluated before therapy were categorized (mainly according to their median values) and used to construct a multivariate Cox survival model. Therapies were classified (ranked) according to the effectiveness as assessed in a univariate analysis. Results: Hemoglobin concentration [hazard ratio (HR) 0.50, P<0.001], sex (HR 0.63, P=0.0009), T stage (HR 1.38, P=0.001), pathology (HR 1.43, P=0.15), performance status (HR 1.60, P=0.002), platelet count (HR 1.46, P=0.005), lymphocyte/neutrophil ratio (HR 0.69, P=0.008), and tumor volume (HR 1.45, P=0.008) significantly influenced OS in a univariable analysis. Treatment also influenced overall survival, with a median survival times of 1.57, 1.90, 0.60 and 0.80 years for ICI, anti EGFR, ALK/ROS and chemotherapy, respectively. Multivariable analysis revealed a significant and independent influence of T stage, hemoglobin concentration, performance status, lymphocyte/neutrophil ratio, and treatment on survival. Treatment, while significant, appeared as a relatively weak independent prognosticator of survival, compared to the other variables. For sensitivity assessment, several options of the basic analysis were performed without altering, however, the qualitative outcomes of the basic analysis. Conclusions: The outcome of this study strongly encourages the routine use of readily available independent prognostic factors for survival such as T stage, hemoglobin concentration, patient performance status, and lymphocyte/neutrophil ratio, regardless of systemic treatment selected for therapy of patients with metastatic or recurrent NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.